Bristol Myers Squibb Company $BMY Position Lifted by Avantax Planning Partners Inc.

Avantax Planning Partners Inc. raised its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 28.7% in the third quarter, Holdings Channel.com reports. The fund owned 86,834 shares of the biopharmaceutical company’s stock after buying an additional 19,342 shares during the quarter. Avantax Planning Partners Inc.’s holdings in Bristol Myers Squibb were worth $5,418,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BMY. Primecap Management Co. CA purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter worth about $1,436,115,000. Legal & General Group Plc purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth about $980,862,000. BlackRock Inc. grew its holdings in shares of Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after purchasing an additional 8,702,106 shares during the period. State Street Corp increased its position in Bristol Myers Squibb by 7.3% during the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock worth $6,093,755,000 after purchasing an additional 7,192,724 shares in the last quarter. Finally, Caisse de depot et placement du Quebec acquired a new stake in Bristol Myers Squibb during the 2nd quarter worth approximately $243,646,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
• Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
• Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
• Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
• Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $62.20 on Friday. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44. Bristol Myers Squibb Company has a 1-year low of $45.26 and a 1-year high of $68.64. The company has a market capitalization of $127.15 billion, a price-to-earnings ratio of 13.79, a PEG ratio of 0.32 and a beta of 0.20. The business has a 50-day moving average of $62.34 and a 200-day moving average of $60.11.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.10 by $0.25. The business had revenue of $13.07 billion for the quarter, compared to the consensus estimate of $12.72 billion. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The company’s revenue was up 6.9% on a year-over-year basis. During the same period last year, the business posted $1.63 EPS. On average, equities analysts anticipate that Bristol Myers Squibb Company will post 6.45 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were given a $0.63 dividend. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.88%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on BMY. HSBC restated a “hold” rating and issued a $65.00 price target (up from $60.00) on shares of Bristol Myers Squibb in a report on Thursday, September 10th. Truist Financial set a $70.00 price objective on shares of Bristol Myers Squibb in a research note on Friday, October 30th. Argus raised shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price objective for the company in a research report on Wednesday, August 5th. Bank of America reissued a “buy” rating on shares of Bristol Myers Squibb in a research note on Friday, October 30th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus target price of $65.46.

Insider Activity at Bristol Myers Squibb

In related news, Director Julia A. Haller sold 3,800 shares of the firm’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the sale, the director directly owned 30,279 shares of the company’s stock, valued at approximately $1,916,963.49. This trade represents a 11.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.05% of the stock is owned by company insiders.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.